Stefan Güssregen holds a position as senior principle scientist within the integrated drug discovery unit at Sanofi in Frankfurt. Prior to joining Sanofi, he received a PhD in theoretical organic chemistry from the University of Würzburg, Germany, that was followed by a position as director of molecular design at Tripos (now Certara) in both the UK and Germany.
He has a broad interest in all aspects of drug design including machine learning (AI) as well physics-based approaches for application in lead generation as well as multi-parametric lead optimization. In his current role, he actively contributed to drug discovery projects with different synthetic modalities ranging from small molecules to peptides and therapeutic proteins, resulting in several compounds entering pre-clinical and clinical phases.
His scientific work has resulted in more than 60 publications in peer-reviewed journals, reviews, and patents.